Ansun Biopharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
14
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
DAS181 for STOP COVID-19
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Ansun Biopharma, Inc.
- Registration Number
- NCT04354389
- Locations
- 🇮🇹
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy
🇮🇹A.O.U Policlinico Di Modena, Modena, Italy
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
- Conditions
- Influenza InfectionSAD-RV Infection and COVID-19
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT04298060
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- Conditions
- Lower Respiratory Tract InfectionParainfluenzaImmunocompromisedCOVID-19
- Interventions
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 274
- Registration Number
- NCT03808922
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
🇺🇸University of Iowa Health Care, Iowa City, Iowa, United States
An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
- Conditions
- Parainfluenza
- Interventions
- Drug: DAS181-F02 Dry Powder in BulkDrug: DAS181-F02 Nebulized Formulation Inhaled Dose
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01924793
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza
- Conditions
- Influenza
- Interventions
- Drug: DAS181-F04 formulationDrug: PlaceboDrug: DAS181-F02 formulation
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 423
- Registration Number
- NCT01740063
- Locations
- 🇺🇸
Nexbio, San Diego, California, United States
- Prev
- 1
- 2
- Next